These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 32524766)

  • 1. Dose equivalency and efficacy of biosimilar erythropoietin stimulating agents: Data from real clinical practice.
    Gaipov A; Issanov A; Mursalova Z; Tulegenova N; Kakim Z; Baizakov M; Tuganbekova S; Aljofan M
    Pharmacol Res Perspect; 2020 Jun; 8(3):e00594. PubMed ID: 32524766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dosing Penalty of Erythropoiesis-Stimulating Agents After Switching From Originator to Biosimilar Preparations in Stable Hemodialysis Patients.
    Minutolo R; Borzumati M; Sposini S; Abaterusso C; Carraro G; Santoboni A; Mura C; Filiberti O; Santoro D; Musacchio R; Imperiali P; Fiorini F; De Nicola L; Russo D
    Am J Kidney Dis; 2016 Jul; 68(1):170-2. PubMed ID: 26879099
    [No Abstract]   [Full Text] [Related]  

  • 3. A population-based study comparing biosimilar versus originator erythropoiesis-stimulating agent consumption in 6,117 patients with renal anaemia.
    Hörbrand F; Bramlage P; Fischaleck J; Hasford J; Brunkhorst R
    Eur J Clin Pharmacol; 2013 Apr; 69(4):929-36. PubMed ID: 23052412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Comparison of Renogen, a Biosimilar Epoetin-a, with the Originator, Eprex, in Chronic Kidney Disease Anemia in Indonesia: A Preliminary Study.
    Hustrini NM; Siregar P; Setiawati A; Nugroho P
    Acta Med Indones; 2019 Jul; 51(3):230-237. PubMed ID: 31699946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switch of ESA therapy from darbepoetin-alpha to epoetin-beta in hemodialysis patients: a single-center experience.
    Biggar P; Ketteler M; Hennemann H; Dömling R
    Clin Nephrol; 2008 Mar; 69(3):185-92. PubMed ID: 18397717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative risk/benefit profile of biosimilar and originator erythropoiesis-stimulating agents (ESAs): data from an Italian observational study in nephrology.
    Motola D; Vaccheri A; Roncadori A; Donati M; Bonaldo G; Covezzoli A; Polidori P; Bianchi S
    Eur J Clin Pharmacol; 2018 Jun; 74(6):805-810. PubMed ID: 29429032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Long-Term Safety of C.E.R.A. Maintenance in Pediatric Hemodialysis Patients with Anemia of CKD.
    Fischbach M; Wühl E; Reigner SCM; Morgan Z; Schaefer F
    Clin J Am Soc Nephrol; 2018 Jan; 13(1):81-90. PubMed ID: 29097481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized double-blind clinical trial of a new human epoetin versus a commercially available formula for anemia control in patients on hemodialysis.
    Picon PD; Pribbernow SC; Prompt CA; Schacher SC; Antunes VV; Mentz BP; Oliveira FL; Souza CM; Schacher FC
    Clinics (Sao Paulo); 2014 Aug; 69(8):547-53. PubMed ID: 25141114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of Switch to Erythropoiesis-Stimulating Agent (ESA) Biosimilars versus Maintenance of ESA Originators in the Real-Life Setting: Matched-Control Study in Hemodialysis Patients.
    Minutolo R; Bolasco P; Chiodini P; Sposini S; Borzumati M; Abaterusso C; Mele AA; Santoro D; Canale V; Santoboni A; Filiberti O; Fiorini F; Mura C; Imperiali P; Borrelli S; Russo L; De Nicola L; Russo D
    Clin Drug Investig; 2017 Oct; 37(10):965-973. PubMed ID: 28779268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and Safety of Switching Originator and Biosimilar Epoetins in Patients with Chronic Kidney Disease in a Large-Scale Italian Cohort Study.
    Belleudi V; Trotta F; Addis A; Ingrasciotta Y; Ientile V; Tari M; Gini R; Pastorello M; Scondotto S; Cananzi P; Traversa G; Davoli M; Trifirò G;
    Drug Saf; 2019 Dec; 42(12):1437-1447. PubMed ID: 31228010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic efficacy of a biosimilar epoetin alfa in hemodialysis patients.
    Harzallah A; Zouaghi K; Dridi A; Boubaker K; Beji S; Ayari M; El Younsi F; Moussa FB; Kheder A
    Saudi J Kidney Dis Transpl; 2015 Jan; 26(1):78-82. PubMed ID: 25579720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous Epoetin Alfa-epbx versus Epoetin Alfa for Treatment of Anemia in End-Stage Kidney Disease.
    Fishbane S; Singh B; Kumbhat S; Wisemandle WA; Martin NE
    Clin J Am Soc Nephrol; 2018 Aug; 13(8):1204-1214. PubMed ID: 29921734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of biosimilar epoetin to increase hemoglobin levels in patients with chemotherapy-induced anemia: real-life clinical experience.
    Kerkhofs L; Boschetti G; Lugini A; Stanculeanu DL; Palomo AG
    Future Oncol; 2012 Jun; 8(6):751-6. PubMed ID: 22443466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hemoglobin maintenance and dosing strategies using intravenous continuous erythropoietin receptor activator in Japanese hemodialysis patients.
    Hirai T; Nishizawa Y; Nakazono H; Asai M; Yamashita H; Sasaki A; Yamashita T; Yamashita K; Shigemoto K; Harada S; Mizuiri S
    Ther Apher Dial; 2013 Oct; 17(5):498-503. PubMed ID: 24107278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subcutaneous epoetin beta in renal anemia: an open multicenter dose titration study of patients on continuous peritoneal dialysis.
    Bárány P; Clyne N; Hylander B; Johansson AC; Simonsen O; Larsson R; Frisenette-Fich C; Svensson B; Helmers C
    Perit Dial Int; 1995; 15(1):54-60. PubMed ID: 7734561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preservation of anemia control and weekly ESA dosage after conversion from PEG-Epoetin beta to darbepoetin alfa in adult hemodialysis patients: the TRANSFORM study.
    Donck J; Gonzalez-Tabares L; Chanliau J; Martin H; Stamatelou K; Manamley N; Farouk M; Addison J
    Adv Ther; 2014 Nov; 31(11):1155-68. PubMed ID: 25367412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erythropoietin-alpha dosage requirements in a provincial hemodialysis population: effect of switching from subcutaneous to intravenous administration.
    Raymond CB; Collins DM; Bernstein KN; Skwarchuk DE; Vercaigne LM
    Nephron Clin Pract; 2006; 102(3-4):c88-92. PubMed ID: 16282700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose conversion ratio in hemodialysis patients switched from darbepoetin alfa to PEG-epoetin beta: AFFIRM study.
    Choi P; Farouk M; Manamley N; Addison J
    Adv Ther; 2013 Nov; 30(11):1007-17. PubMed ID: 24173670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, immunogenicity and efficacy of subcutaneous biosimilar epoetin-α (HX575) in non-dialysis patients with renal anemia: a multi-center, randomized, double-blind study.
    Haag-Weber M; Eckardt KU; Hörl WH; Roger SD; Vetter A; Roth K
    Clin Nephrol; 2012 Jan; 77(1):8-17. PubMed ID: 22185963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
    Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
    Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.